Replimune Group, Inc. Insider Trading Activity

Q: What did Replimune (REPL) director Kapil Dhingra report on this Form 4?

Kapil Dhingra reported receiving a grant of stock options for 44,500 shares of Replimune Common Stock. The award is compensation-related, not an open-market trade, and gives the right to buy shares at a fixed exercise price in the future.

Q: How many Replimune (REPL) shares are covered by the new stock options?

The new stock option award covers 44,500 underlying shares of Replimune Common Stock. These options represent the right, but not the obligation, to purchase that number of shares once the options are vested and exercisable, subject to their terms.

Q: What is the exercise price of Kapil Dhingra’s Replimune (REPL) stock options?

The stock options have an exercise price of $7.61 per share. This means Dhingra can buy Replimune Common Stock at $7.61 for each option exercised, once vested and before the options expire, regardless of the market price at that time.

Q: When do Kapil Dhingra’s Replimune (REPL) stock options expire?

The reported stock options have an expiration date of April 1, 2036. After this date, any unexercised options will lapse. The period between the vesting date in 2027 and expiration in 2036 is the window during which vested options may be exercised.

Replimune Group director Kapil Dhingra received a grant of stock options covering 44,500 shares of Common Stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Replimune Group director Kapil Dhingra received a grant of stock options covering 44,500 shares of Common Stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036. All underlying shares vest together on April 1, 2027, and no open-market buy or sell occurred.

Insider Trade Summary

Grant/Award: 44,500 shares

Grant/Award 1 txn

Insider Dhingra Kapil

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	44,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 44,500 contracts (Direct)

Footnotes (1)

F1. The shares underlying this option vest entirely on April 1, 2027.

Key Figures

Options granted: 44,500 options Exercise price: $7.61 per share Underlying shares: 44,500 shares +3 more

6 metrics

Options granted 44,500 options Stock Option grant to director on April 1, 2026

Exercise price $7.61 per share Exercise price for the 44,500 stock options

Underlying shares 44,500 shares Common Stock underlying the reported stock options

Vesting date April 1, 2027 All shares underlying the option vest on this date

Expiration date April 1, 2036 Option expiration for the granted stock options

Post-transaction options held 44,500 options Total derivative holdings reported after this grant

Key Terms

Stock Option (right to buy), exercise price, expiration date, underlying security, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price": "7.6100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date": "2036-04-01T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title": "Common Stock""

vesting financial

"The shares underlying this option vest entirely on April 1, 2027."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Replimune (REPL) director Kapil Dhingra report on this Form 4?

Kapil Dhingra reported receiving a grant of stock options for 44,500 shares of Replimune Common Stock. The award is compensation-related, not an open-market trade, and gives the right to buy shares at a fixed exercise price in the future.

How many Replimune (REPL) shares are covered by the new stock options?

The new stock option award covers 44,500 underlying shares of Replimune Common Stock. These options represent the right, but not the obligation, to purchase that number of shares once the options are vested and exercisable, subject to their terms.

What is the exercise price of Kapil Dhingra’s Replimune (REPL) stock options?

The stock options have an exercise price of $7.61 per share. This means Dhingra can buy Replimune Common Stock at $7.61 for each option exercised, once vested and before the options expire, regardless of the market price at that time.

When do the newly granted Replimune (REPL) stock options vest?

According to the footnote, the shares underlying this option vest entirely on April 1, 2027. This single vesting date means none of the options are exercisable before that day, after which the full grant becomes eligible for exercise.

When do Kapil Dhingra’s Replimune (REPL) stock options expire?

The reported stock options have an expiration date of April 1, 2036. After this date, any unexercised options will lapse. The period between the vesting date in 2027 and expiration in 2036 is the window during which vested options may be exercised.

Did this Replimune (REPL) Form 4 show any stock being bought or sold on the market?

No open-market purchases or sales were reported. The Form 4 shows an acquisition by grant of a stock option, with transaction code “A” and indicators that it is a grant or award, rather than a buy or sell transaction in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/07/2026 - 09:09 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dhingra Kapil

(Last)

(First)

(Middle)

C/O REPLIMUNE GROUP, INC.

500 UNICORN PARK DRIVE, SUITE 303

(Street)

WOBURN

MASSACHUSETTS

01801

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Replimune Group, Inc. [ REPL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$7.61	04/01/2026		A		44,500		⁽¹⁾	04/01/2036	Common Stock	44,500	$0	44,500	D

Explanation of Responses:

1. The shares underlying this option vest entirely on April 1, 2027.

Remarks:

This Form 4 is being filed late due to inadvertent administrative error.

	/s/ Shawn Glidden, attorney-in-fact	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR